VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527171431/en/
Jessica Atkinson, New CBO at VectorY Therapeutics
Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors.
'I'm delighted to welcome Jessica to VectorY,' said Jim Scibetta, chief executive officer of VectorY Therapeutics. 'Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team.'
'VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases,' said Atkinson. 'I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success.'
Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient.
About VectorY
VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see www.vectorytx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250527171431/en/
CONTACT: VectorY Therapeutics B.V.
E-mail:[email protected]
Tel: +31 20 226 8020
Vigo Consulting (Media)
Melanie Toyne-Sewell / Rozi Morris
E-mail:[email protected]
Tel: +44 207 390 0237 / +44 20 7390 0231
KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE NEUROLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: VectorY Therapeutics
Copyright Business Wire 2025.
PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
http://www.businesswire.com/news/home/20250527171431/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced that it is monitoring a safety issue with Boston Scientific Corporation's ENDOTAK RELIANCE defibrillation leads, which are used with implantable cardioverter-defibrillators to prevent sudden cardiac death. Earlier this year, the company sent a letter to healthcare providers on July 24, warning that calcification of the leads' expanded polytetrafluoroethylene/ePTFE coating could lead to a gradual increase in low-voltage shock impedance/LVSI. This can reduce the effectiveness of life-saving shocks and even result in patient death. A surgeon examining a patient's brain in an operating room, paramedics nearby. The affected leads were manufactured and distributed between 2002 and 2021 and are no longer available. As of July 24, Boston Scientific had reported 386 serious injuries and 16 deaths linked to this issue. The FDA has categorized this as a potentially high-risk problem and is actively reviewing data to determine further regulatory action. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has 2 segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Years at work: Which European countries have the longest average working life?
Life expectancy has been rising across the EU in recent decades and with that retirement ages are increasing in many countries, meaning people are spending more years on the job. In 2024, the average expected working life in the EU was 37.2 years, according to Eurostat. This represents an increase of 2.4 years, or 7%, compared to 2014, when it was 34.8 years. Within the EU, expected working life ranges from 32.7 years in Romania to 43.8 years in the Netherlands. When EU candidates and EFTA countries are included, it varies from 30.2 years in Turkey to 46.3 years in Iceland. But what explains the wide gap in expected working life across Europe? How many years do Europeans work for? While there are some exceptions, the expected duration of working life in Europe generally follows geographical patterns. Northern European countries—particularly the Nordic region—lead with the longest working lives. Iceland tops the list, followed by the Netherlands (43.8 years) and Sweden (43 years). Denmark (42.5 years), Norway (41.2 years), and Finland (39.8 years) also report high figures, all ranking in the top 10 of 35 European countries. Western European countries also tend to have above-average working life durations. Switzerland (42.8 years), Ireland (40.4 years) and Germany (40 years) all exceed 40 years and rank in the top 10. However, France (37.3 years), Belgium (35 years), and Luxembourg (35.6 years) fall closer to, or below, the EU average of 37.2 years. The most recent available figure for the UK is from 2018, when it was 39.2 years. Considering the rising trend across the EU, the current figure is likely to be higher. The figures are more mixed in Southern Europe. While Portugal (39.3 years) and Malta (39 years) show relatively long working lives, Italy (32.8 years), Greece (34.8 years), and Spain (36.5 years) are significantly lower. Eastern European countries mostly fall around or just below the EU average. Hungary (37.4 years) performs moderately, while others—such as Romania (32.7 years) and Bulgaria (34.8 years)—report significantly shorter expected working lives. The shortest durations are observed in Southeastern Europe and the Balkans, including Turkey (30.2 years), North Macedonia (31.5 years), and Montenegro (32.1 years). All three are EU candidate countries, with the figures for North Macedonia and Montenegro based on 2018 data. Related Surviving retirement: Where do older Europeans get their money? Family benefits in Europe: Which countries offer the best social security? Why does the average working life differ? As these figures show, the average expected working life significantly differs across Europe. But, why? Prof. Moritz Hess from the University of Applied Sciences Niederrhein noted that the duration of working life, as well as labour force participation in Europe, differs due to several reasons. 'First, the demand side plays an important role: if employers need workers, this increases labour force participation and extends the duration of working life,' he told Euronews Business. 'Second, the institutional context matters, particularly in relation to pension and labour market regulations. A key factor in this regard is the official retirement age: the higher it is, the longer the expected duration of working life. The fewer early retirement options a pension system offers, the longer people are likely to remain in the workforce,' he added. Prof Hess also explained that ageism—discrimination based on age—also plays a role. In countries where older workers are not discriminated against and their contributions are valued, they are more likely to want to continue working, which leads to longer working lives. Timo Anttila, Senior Lecturer at University of Jyväskylä in Finland, pointed out that the family models of countries, such as single/dual earners, pension systems and family care models are possibly important factors having an impact on work life duration expectancy. Related Warning signs in Europe's job market: Workers now brace for tariff effects Labour force participation rate matters 'Most of the duration of working life can be explained by the labour force participation rate,' Eurostat finds. In general, countries with lower participation rates tend to have shorter average working lives. The chart above illustrates this relationship for the total population, comparing each country's expected working life with its labour force participation rate. The labour force participation rate explains approximately 81.5% of the variance in expected working life according to Eurostat. Several countries have already introduced measures to raise the retirement age. By 2060, the OECD estimates that the average retirement age across the EU will be near 67, with some nations expected to exceed 70. Euronews article —Europe's rising retirement ages— explains the current retirement ages across Europe as well as projections for future increases. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données
CBS News
11 hours ago
- CBS News
Price of vegetables shoots up nearly 40% in Massachusetts. What's behind the surge?
The price of wholesale and dry vegetables shot up nearly 40% compared to this time last year and a Massachusetts expert spoke with WBZ-TV about what's behind the surge. As food prices go up across the country, Boston's Haymarket stands as one of few places where shoppers can still find a deal. The question is, for how much longer? According to the Bureau of Labor Statistics, from June to July, the cost of wholesale vegetables skyrocketed 38.9%, leaving market vendors feeling pressured to balance rising supply costs with customers who expect the same low prices. "Sometimes it's so high, it's ridiculous. You can't sell anything to make a profit," said Henry, who's been vending at Haymarket for years. TT Tilleo, another vendor, echoed that sentiment saying, "We pay more and our customers over here still want the same deals." Tufts University professor William Masters, who teaches at the Friedman School of Nutrition and Department of Economics, said the price increase shouldn't be a surprise for seasoned vendors. "Thirty-eight percent is a big jump, and if you're a vegetable trader, you've seen that before," said Masters. Masters said that the price surge is part of a random fluctuation. "It has to do with weather, has to do with some supply disruption or a spike in demand," he explained. According to the professor, trends like tariffs and fewer immigrant workers, will only cause vegetables prices to soar even higher. "If you look at the statistics, you can begin to have a sense of how the randomness is big and real, and the trends are big and real," Masters said. "We see the consumer in the end, after a period of weeks, paying the bulk of the tariffs." Despite the challenges, vendors said they're committed to keeping the market's bargaining tradition alive. "We're still over here just trying to survive and help everybody out because you know, it's a give and take," said Tilleo.
